Bio-Rad wins appeal in 10x Genomics patent infringement ruling

By The Science Advisory Board staff writers

August 5, 2020 -- Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed a patent that had been exclusively licensed to Bio-Rad by the University of Chicago.

The Court of Appeals also upheld the lower court's finding for $23.9 million in monetary damages, awarding Bio-Rad a 15% royalty on past and future sales, and a permanent injunction against 10x's Single Cell 3' gene expression products, Single Cell assay for transposase accessible chromatin (ATAC)-seq products, and Single Cell V(D)J products that were found to infringe U.S. Patent 8,889,083, Bio-Rad said.

However, the Court of Appeals also withdrew the District Court's injunction with respect to 10x's Linked-Read and copy number variation (CNV) product lines and reversed the District Court's decision on infringement of two other patents asserted by Bio-Rad. The company said that it does not believe these aspects of the decision will have a material impact on the overall result and is evaluating its options for further review.

Bio-Rad's Q2 revenue drops
Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year.
Bio-Rad posts increased Q1 revenue during pandemic
For the quarter revenue increased to $571.6 million, compared with $554 million in the first quarter of 2019. Meanwhile, net income in the first...
Bio-Rad acquires single-cell analysis company
Bio-Rad Laboratories has acquired Celsee, a company that offers instruments and consumables for single-cell analysis.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter